Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ascendis Pharma A/S - American Depositary Shares (NQ:ASND)

211.74 +7.69 (+3.77%)
Streaming Delayed Price Updated: 12:48 PM EDT, Oct 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ascendis Pharma A/S - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
22 Stocks Moving in Thursday's Pre-Market Session
Gainers Good Works Acquisition Corp. (NASDAQ: GWAC) rose 29.8% to $13.01 in pre-market trading. Good Works Acquisition and Cipher Mining reported shareholder approval of business... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Ascendis Pharma (NASDAQ:ASND) st... 
Via Benzinga
The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug
ere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 24) Agenus Inc. (NASDAQ: AGEN)... 
Via Benzinga
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc... 
Via Benzinga
Expert Ratings For Ascendis Pharma
Ascendis Pharma (NASDAQ:ASND) has observed the following ... 
Via Benzinga
Earnings Scheduled For August 25, 2021
Companies Reporting Before The Bell • Jiayin Gr (NASDAQ:JFIN) is projected to report quarterly earnings at $0.21 per share on revenue of $54.80 million. • Viomi... 
Via Benzinga
The Week Ahead In Biotech: Cara FDA Decision, Ascendis Earnings, Aileron Data Presentation And More
Biotech stocks swayed back and forth before ending the week lower. With earnings news dying down and an empty initial public offerings calendar, it was broader market cues,... 
Via Benzinga
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI... 
Via Benzinga
The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22) Bio-Techne Corporation (... 
Via Benzinga
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. 
Via Talk Markets
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19) Cytokinetics, Incorporated... 
Via Benzinga
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. The U.S. Federal... 
Via Benzinga
Ascendis Pharma's TransCon hGH FDA Review Pushed Backed By Three Months
The FDA has extended the ongoing review of the marketing application of Ascendis Pharma A/S's (NASDAQ: ASND) TransCon hGH (lonapegsomatropin) for the... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates
The FDA review machinery worked overtime in May, completing reviews of several drug applications. Except for stray rejections or delays, the agency churned out mostly positive... 
Via Benzinga
What 5 Analyst Ratings Have To Say About Ascendis Pharma
Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 1 0 0 1... 
Via Benzinga
Earnings Scheduled For June 1, 2021
Companies Reporting Before The Bell • 36KR Holdings (NASDAQ:KRKR) is expected to report quarterly loss at $0.11 per share on revenue of $10.82 million. • Canopy... 
Via Benzinga
Ascendis Pharma A/S (ASND) Q1 2021 Earnings Call Transcript
ASND earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
The Week Ahead In Biotech (May 23-29): Eton, Lantheus FDA Decisions, Adcom Test For Provention, Chiasma Data Presentation
Biotech stocks advanced in the week ended May 21, as risk aversion forced traders to buy into defensives. As earnings news flow tapered, stocks took cues from clinical readouts.... 
Via Benzinga
The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB)... 
Via Benzinga
Ascendis Pharma's TransCon PTH Provides Durable Benefit, Is Well Tolerated Even After One Year Treatment In Hypoparathyroidism
Ascendis Pharma A/S (NASDAQ: ASND) has announced preliminary 58-week results from the continuing open-label extension (OLE) portion of the Phase 2 PaTH... 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
During Monday's morning trading, 29 companies set new 52-week lows. Intriguing Points: Ascendis Pharma (NASDAQ:ASND) is the largest company in terms of market... 
Via Benzinga
Earnings Scheduled For May 27, 2021
Companies Reporting Before The Bell • Royal Bank of Canada (NYSE:RY) is likely to report quarterly earnings at $2.48 per share on revenue of $11.77 billion. •... 
Via Benzinga
The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10) AbbVie Inc. (NYSE: ABBV) -... 
Via Benzinga
The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 15) Alexion Pharmaceuticals,... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.